Madrigal Pharmaceuticals, Inc. (MDGL)
523.69
-16.20
(-3.00%)
USD |
NASDAQ |
May 15, 16:00
524.10
+0.41
(+0.08%)
Pre-Market: 20:00
Madrigal Pharmaceuticals Research and Development Expense (Quarterly) : 108.31M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Insmed, Inc. | 209.48M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| PTC Therapeutics, Inc. | 100.87M |
| Protagonist Therapeutics, Inc. | 46.74M |
| Altimmune, Inc. | 16.17M |